Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose safety and PK of oral NNC0385-0434 in healthy Japanese men
jRCT2071210055Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNC0385-0434 in familial hypercholesterolemia (FH) and hypercholesterolemia (4 arms), sponsored by Novo Nordisk. Primary endpoint: Treatment-emergent adverse events. Started Aug 2021; status: completed.
02
Drugs
NNC0385-0434
03
Conditions
familial hypercholesterolemia (FH)hypercholesterolemia
Beyond the preview
Go deeper on jRCT2071210055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210055.